Oncology Breast CNS Chemotherapy Endocrine GI GU Geriatric Gynecologic GYN-OB Head and Neck Haematology Immunotherapy Lung Melanoma Skin NET Paediatric Pathology Sarcoma Surgery Targeted Therapy Translational

Durable Responses to JCAR017 Observed in High-Risk DLBCL

2018-03-29 10:30:12

Responses to lisocabtagene maraleucel have been potent and durable in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. Separate exploratory analyses of this population treated with liso-cel found that high tumor burden and a series of in ammatory biomarkers were associated with high chimeric antigen receptor T-cell expansion and higher rates of cytokine release syndrome and neurotoxicity.

Source

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply